Search research articles
Contact Us
Filters
Showing results (21-30 of 45) with videos related to
Page
of 5
Sort By:
Infectious Diseases of Poverty
|
May 17, 2020
The China tuberculosis clinical trials consortium network: a model for international TB clinical trials capacity building
Yu-Hong Liu, Shu Chen, Jing-Tao Gao, et al.
Mbio
|
November 5, 2015
Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy
Ashley N Brown, George L Drusano, Jonathan R Adams, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 29, 2012
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide
Jacques Grosset, Deepak Almeida, Paul J Converse, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 10, 2002
Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039
Keith Chirgwin, Richard Hafner, Catherine Leport, et al.
The Journal of Infectious Diseases
|
March 27, 2012
Innovative trial designs are practical solutions for improving the treatment of tuberculosis
Patrick P J Phillips, Stephen H Gillespie, Martin Boeree, et al.
Nature Immunology
|
May 20, 2018
Tuberculous meningitis: a roadmap for advancing basic and translational research
Sanjay K Jain, David M Tobin, Elizabeth W Tucker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 15, 2003
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome
Constance A Benson, Paige L Williams, Judith S Currier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 25, 2004
Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy
Mitchell Goldman, Robert Zackin, Carl J Fichtenbaum, et al.
American Journal of Respiratory and Critical Care Medicine
|
January 17, 2020
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial
Kelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 5, 2020
Reply to Decroo <i>et al.</i>: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
Kelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 45) with videos related to
Sort By:
Page
of 5
Infectious Diseases of Poverty
|
May 17, 2020
The China tuberculosis clinical trials consortium network: a model for international TB clinical trials capacity building
Yu-Hong Liu, Shu Chen, Jing-Tao Gao, et al.
Mbio
|
November 5, 2015
Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy
Ashley N Brown, George L Drusano, Jonathan R Adams, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 29, 2012
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide
Jacques Grosset, Deepak Almeida, Paul J Converse, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 10, 2002
Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039
Keith Chirgwin, Richard Hafner, Catherine Leport, et al.
The Journal of Infectious Diseases
|
March 27, 2012
Innovative trial designs are practical solutions for improving the treatment of tuberculosis
Patrick P J Phillips, Stephen H Gillespie, Martin Boeree, et al.
Nature Immunology
|
May 20, 2018
Tuberculous meningitis: a roadmap for advancing basic and translational research
Sanjay K Jain, David M Tobin, Elizabeth W Tucker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 15, 2003
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome
Constance A Benson, Paige L Williams, Judith S Currier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 25, 2004
Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy
Mitchell Goldman, Robert Zackin, Carl J Fichtenbaum, et al.
American Journal of Respiratory and Critical Care Medicine
|
January 17, 2020
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial
Kelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 5, 2020
Reply to Decroo <i>et al.</i>: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
Kelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, et al.
Page
of 5